Indian Journal of Critical Care Medicine
Medknow Publications on behalf of the Indian Society of Critical Care Medicine
Vol. 11, No. 1, 2007, pp. 29-35
Bioline Code: cm07006
Full paper language: English
Document type: Research Article
Document available free of charge
Indian Journal of Critical Care Medicine, Vol. 11, No. 1, 2007, pp. 29-35
© Copyright 2007 Indian Journal of Critical Care Medicine.
Preventing acute renal failure is crucial during acute tumor lysis syndrome|
Darmon, Michael; Thiery, Guillaume & Azoulay, Elie
Tumour Lysis syndrome (TLS) is characterized by the massive destruction of tumoral cells and the release in the extracellular space of their content. While TLS may occur spontaneously before treatment, it usually develops shortly after the initiation of cytotoxic chemotherapy. These metabolites can overwhelm the homeostatic mechanisms and cause hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia. Moreover, TLS may lead to an acute renal failure (ARF). In addition to the hospital mortality induced by the acute renal failure itself, development of an ARF may preclude optimal cancer treatment. Therefore, prevention of the acute renal failure during acute tumor lysis syndrome is mandatory. The objective of this review is to describe pathophysiological mechanisms leading to acute tumor lysis syndrome, clinical and biological consequences of this syndrome and to provide up-to-date guidelines to ensure prevention and prompt management of this syndrome.
Acute renal failure, hyperkalemia, hyperphosphatemia, hyperuricemia, intensive care unit, leukemia, non-Hodgkin′s lymphoma, urate nephropathy
Alternative site location: http://www.ijccm.org/